Insights
Search Results
Client Highlights
3.02.26
Wilson Sonsini Advises Sense on Strategic Investment from Analog Devices
On January 27, 2026, Sense, a leader in grid edge intelligence, announced it has received a strategic investment from Analog Devices, Inc. (ADI), a global semiconductor leader that bridges the physical and digital worlds to enable breakthroughs at the Intelligent Edge. This new investment enables further development of grid edge intelligence and management solutions for grid operators. Together, the companies will work with smart meter developers and others in the energy industry to accelerate the adoption of high-performance data and computation capabilities to enable a smarter grid. Wilson Sonsini Goodrich & Rosati advised Sense on the transaction.
Client Highlights
11.17.25
Wilson Sonsini Advises onX on Strategic Investment from TCV
On November 3, 2025, onX, a pioneer in digital outdoor navigation and mapping software, announced a strategic investment from TCV, a leading growth equity firm known for supporting enduring consumer technology brands. The partnership brings additional operational expertise and long-term support as onX continues to scale its suite of adventure-specific navigation apps and redefine the outdoor experience. The company's existing investors, including Summit Partners, Madison Valley Partners, and onX founder Eric Siegfried, will remain active board members. Wilson Sonsini Goodrich & Rosati advised onX on the transaction.
Client Highlights
5.15.25
Wilson Sonsini Advises Entrata on $200 Million Investment from Blackstone
On May 15, 2025, Entrata, a leading operating system for multifamily communities, announced a $200 million minority investment from funds managed by Blackstone at a $4.3 billion valuation. This investment comes as Entrata is moving forward on its next chapter of growth, serving the rental housing industry through innovative technology that streamlines operations for property managers and elevates the living experience for millions of residents. Wilson Sonsini Goodrich & Rosati advised Entrata on the transaction.
Entrata’s suite of solutions offers a centralized platform for managing various aspects of a property, including accounting, purchasing, facilities, and leasing, among others. Over the past two decades Entrata has emerged as a leader in property management technology, building a comprehensive operating system in rental housing.
Entrata’s suite of solutions offers a centralized platform for managing various aspects of a property, including accounting, purchasing, facilities, and leasing, among others. Over the past two decades Entrata has emerged as a leader in property management technology, building a comprehensive operating system in rental housing.
Client Highlights
3.17.25
Wilson Sonsini Advises Warburg Pincus on Stake Increase in United Family Healthcare
On March 13, 2025, United Family Healthcare (UFH), a leading high-end private healthcare services company in China, announced that Warburg Pincus, a global private equity investment leader, would further increase its stake in UFH. Upon completion of the transaction, Warburg Pincus will become a significant shareholder of UFH and secure a seat on the board of directors, and Fosun Pharma will exit from UFH.
Client Highlights
8.02.24
Wilson Sonsini Advises Qatalyst Partners on R1 RCM Inc.'s $8.9 Billion Acquisition by TowerBrook Capital Partners and Clayton, Dubilier & Rice
On July 31, 2024, R1 RCM Inc. (R1) announced that they have entered into a definitive agreement pursuant to which investment funds affiliated with TowerBrook Capital Partners and Clayton, Dubilier & Rice will acquire R1, a leading provider of technology-driven solutions that transform the patient experience and financial performance of healthcare providers. Transaction negotiations were led by a Special Committee of the Board of Directors of R1 (the Special Committee), which, as previously announced on March 11, 2024, was formed to evaluate strategic alternatives, advised by independent legal and financial advisors, and following the recommendation of the Special Committee, R1’s Board of Directors approved the transaction. Wilson Sonsini Goodrich & Rosati advised Qatalyst Partners, which served as a financial advisor to the Special Committee on the transaction.
Client Highlights
6.21.24
Wilson Sonsini Advises Ascentage Pharma on HK$585.77 Million (US$75 Million) Equity Investment from Takeda International in Connection with the Exclusive Global License for HQP1351 (olverembatinib)
Ascentage Pharma Group International (Ascentage Pharma) and Takeda Pharmaceuticals International AG (Takeda International) entered into an exclusive option agreement on June 14, 2024, where Takeda International is granted with an exclusive option to enter into an exclusive license agreement for HQP1351 (olverembatinib), a core drug candidate of Ascentage Pharma. In connection with such exclusive global arrangement, Ascentage Pharma and Takeda International also entered into a securities purchase agreement, pursuant to which Takeda International made a HK$585.77 million (US$75 million) equity investment in Ascentage Pharma to subscribe 24,307,322 shares of Ascentage Pharma at a purchase price of HK$24.09850 per share. The closing of such equity investment took place on June 20, 2024.
News Articles
5.15.24
Two Firm-Led Deals Win China Business Law Journal's "Deals of the Year" Awards
China Business Journal named two deals led by Wilson Sonsini Goodrich & Rosati among its 2023 "Deals of the Year." The publication selected 191 deals across 12 categories that "stood out" in its vast submission database of Chinese and international law firms, backed by independent observation and continued coverage of China’s legal market, and considering factors including overall significance, complexity, innovative nature, and deal size.
Client Highlights
3.27.24
Wilson Sonsini Advises Boyu Capital in Connection with US$587 Million Series A Investment in GDS International
On March 26, 2024, GDS Holdings Limited (GDSH), a leading developer and operator of high-performance data centers in China and South East Asia, announced that its wholly-owned subsidiary, DigitalLand Holdings Limited, or GDS International, that acts as the holding company for GDSH’s international data center assets and operations, has entered into definitive agreements for certain private equity investors, including Boyu Capital, to subscribe for US$587 million of Series A convertible preferred shares newly issued by GDS International. Wilson Sonsini Goodrich & Rosati represented Boyu Capital in connection with the transaction.
Client Highlights
8.03.23
Wilson Sonsini Advises Forte Biosciences on $25 Million Financing
On August 1, 2023, biopharmaceutical company Forte Biosciences announced key R&D updates for its product candidate FB-102 (a proprietary molecule with potentially broad autoimmune applications including in such indications as graft versus host disease, vitiligo, and alopecia areata) as well as the closing of $25 million in financing to support the advancement of FB-102. Investors include Alger, BVF Partners, Farallon Capital Management, Perceptive Advisors, and Tybourne Capital Management.
Client Highlights
6.01.23
Firm Advises 4me on Strategic Investment
On May 25, 2023, SaaS-based IT service management software vendor 4me announced a strategic growth investment led by growth equity firm PSG. Wilson Sonsini Goodrich & Rosati advised 4me on the transaction.
Along with the investment, 4me announced that Kevin McGibben was named as CEO and chairman, and that co-founders Cor Winkler Prins, Laurens Pit, and Mathijs Sterk will continue their involvement in the business.
Along with the investment, 4me announced that Kevin McGibben was named as CEO and chairman, and that co-founders Cor Winkler Prins, Laurens Pit, and Mathijs Sterk will continue their involvement in the business.
Newsletters
4.26.23
2022 Technology and Life Sciences PIPE Report
In this inaugural issue, we present analysis related to 108 private investments in public equity (PIPEs) by U.S.-based technology and life sciences companies between January 1 and December 31, 2022, in which each company raised at least $10 million.
Client Highlights
9.22.22
Wilson Sonsini Advises Aadi Bioscience, Inc. on $72.5 Million Private Placement Equity Financing
On September 22, 2022, Aadi Bioscience, Inc., a commercial-stage biopharmaceutical company focused on precision therapies for genetically-defined cancers with alterations in mTOR pathway genes, announced it has entered into a securities purchase agreement with a new accredited investor and certain existing investors to issue and sell an aggregate of 3,373,526 shares of its common stock at a price of $12.50 per share, reflecting the closing price on September 21, 2022 on NASDAQ, and pre-funded warrants to purchase up to an aggregate of 2,426,493 shares of common stock at a purchase price of $12.4999 per pre-funded warrant share, through a private investment in public equity (PIPE) financing. The Pre-Funded Warrants will have an exercise price of $0.0001 per share of common stock, to be immediately exercisable and remain exercisable until exercised in full. Aadi Bioscience anticipates the gross proceeds from the PIPE to be approximately $72.5 million, before deducting any offering related expenses. The financing is expected to close on September 26, 2022, subject to customary closing conditions.